MOR103 Presentation - MorphoSys

More documents

Recommendations

Info

Concomitant treatment of RA Medication Class Placebo N=27 0.3 mg/kg N=24 MOR 103 1.0 mg/kg N=22 1.5 mg/kg N=23 MTX 78% (21) 75% (18) 64% (14 ) 83% (19 ) Other DMARD # 22% (6) 17% (4 ) 18% (4) 9% (2 ) Glucocorticosteroids 70% (19) 83% (20) 64% (14) 65% (15) NSAIDS 48% (13) 54% (13 ) 59% (13) 52% (12) # Sulfasalazine, Hydroxychloroquine, Leflunomide ACR/ARHP 2012 – Washington DC – November 10-14, 2012
Patient Disposition Placebo (n=27) Prematurely terminated (n=5) AE (n=1) Consent withrawn (n=2) Other (n=2) Completed study (n=22) ACR/ARHP 2012 – Washington DC – November 10-14, 2012 MOR103 0.3 mg/kg (n=25) Randomized not treated (n=1) Prematurely terminated (n=3) Non-permitted therapy (n=1) Start of new RA treatment (n=1) Other (n=1) Completed study (n=21) Randomized (n=98) Screened (n=288) MOR103 1.0 mg/kg (n=22) Prematurely terminated (n=3) Non-permitted therapy (n=2) Start of new RA treatment (n=1) Completed study (n=19) Failed to meet inclusion criteria (n=190) MOR103 1.5 mg/kg (n=24) Randomized not treated (n=1) Prematurely terminated (n=0) Completed study (n=23)
Page 1 and 2: Abstract-Number: L11 First in Patie
Page 3 and 4: Disclosures • F. Behrens, M. Oste
Page 5 and 6: Anti-GM-CSF Monoclonal Antibody (MO
Page 7 and 8: Study design 0.3 mg/kg MOR103 (n=25
Page 9: Baseline Disease Characteristics Ch
Page 13 and 14: ACR Response at Week 4 Percentage o
Page 15 and 16: EULAR Response at Week 4 Percentage
Page 17 and 18: Change of Synovitis by MRI Analysis
Page 19 and 20: Acknowledgements Investigators �
Page 21 and 22: Geographic Distribution of Patients
Page 23: DAS28 Response to Treatment MOR103

MOR103 Presentation - MorphoSys

Create successful ePaper yourself

Delete template?

Save as template?